Company Profile

PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Employees

Sector

Biotechnology & Medical Research

More about the company

12-31	The Top Performers and Biggest Flops of the SRD in 2025
25-09-16	PHAXIAM Therapeutics S.A.(ENXTPA:PHXM) dropped from Next Biotech Index	CI
25-06-18	Phaxiam Therapeutics Announces The Suspension Of Trading In Its Shares Until Delisting	RE
25-06-12	Phaxiam Therapeutics Announces Judicial Liquidation And Delisting	RE
25-06-05	Phaxiam Therapeutics Says Postponement Of The Offer Review Hearing	RE
25-05-05	A month of zero gains on the stock market in April?
25-03-14	Phaxiam Therapeutics Announces Launch Of Process To Find Buyers In Context Of Its Receivership Procedure	RE
25-03-14	PHAXIAM Therapeutics Announces the Launch of A Process to Find Buyers in the Context of Its Receivership Procedure	CI
25-03-06	Phaxiam Therapeutics Says Commercial Court Of Lyon To Open Judicial Receivership Procedure	RE
25-03-06	Phaxiam: in receivership proceedings
25-03-06	Phaxiam Therapeutics Announces Postponement of Its 2024 Financial Results Publication	CI
25-03-06	Phaxiam Therapeutics Seeks Trading Suspension on Euronext Paris	MT
25-03-06	Phaxiam: listing suspended pending a press release

25-06-18	PHAXIAM Therapeutics S A : Inside Information / Other news releases	PU
25-06-18	PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting	BU
25-06-12	PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting	BU
25-06-05	PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing	BU
25-05-22	PHAXIAM Therapeutics: Postponement of the Offer Review Hearing	BU

12-31	Les tops et les flops du SRD en 2025
25-10-14	Smalls Caps : Les derniers choix des stars de la gestion
25-06-18	Phaxiam : suspension de la cotation de son titre
25-06-18	Phaxiam Therapeutics : suspension de l'action avant la radiation
25-06-18	PHAXIAM Therapeutics S A : Informations privilégiées / Autres communiqués

Manager	Title	Age	Since
Thibaut du Fayet CEO	Chief Executive Officer	58	2023-06-22
Eric Soyer DFI	Director of Finance/CFO	59	2023-06-22
Cindy Fevre CTO	Chief Tech/Sci/R&D Officer	-	2023-06-22

Director	Title	Age	Since
Didier Hoch CHM	Chairman	70	2023-06-22
Philippe Archinard BRD	Director/Board Member	66	2023-06-22
Martine George BRD	Director/Board Member	78	2023-06-22

PHAXIAM Therapeutics S.A. Stock Nasdaq

Stocks

ERYP

US29604W2070

Biotechnology & Medical Research

Latest news : PHAXIAM Therapeutics S.A.

Press Releases : PHAXIAM Therapeutics S.A.

News in other languages : PHAXIAM Therapeutics S.A.

Quotes and Performance

Managers and Directors : PHAXIAM Therapeutics S.A.

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHAXIAM THERAPEUTICS S.A.	-2.24%	+8.54%	-	-	1.16M
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	70.64B
ARGENX SE	+1.09%	+2.51%	+49.34%	+93.39%	66.11B
BIONTECH SE	-1.03%	+0.46%	+8.14%	-5.28%	27.98B
INSMED INCORPORATED	-2.41%	-2.95%	-9.77%	+455.82%	26.51B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	-0.78%	+63.02%	+11.82%	26.44B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	20.4B
GENMAB A/S	+0.37%	+1.21%	+36.55%	-15.78%	20.17B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.57%	-5.02%	+12.56%	+526.99%	15.99B
EXELIXIS, INC.	-1.50%	+2.92%	+43.50%	+151.30%	13.69B
Average	-0.38%	+0.99%	+59.31%	+193.58%	31.99B
Weighted average by Cap.	+0.64%	+0.65%	+56.40%	+154.56%